Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

SILIQ

BRODALUMAB

Standard Dose
210MG/1.5ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary

Approval overview SILIQ is listed in Drugs@FDA under application 761032 (BLA).

Review priority: N/A Marketing status: Prescription Active ingredient BRODALUMAB Form and strength INJECTABLE;INJECTION - 210MG/1.5ML Sponsor VALEANT LUXEMBOURG Submission history Latest submission status date: 2026-02-27 00:00:00.

Structured Monograph

Clinical summary

Approval overview SILIQ is listed in Drugs@FDA under application 761032 (BLA). Review priority: N/A Marketing status: Prescription Active ingredient BRODALUMAB Form and strength INJECTABLE;INJECTION - 210MG/1.5ML Sponsor VALEANT LUXEMBOURG Submission history Latest submission status date: 2026-02-27 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: N/A

Interaction Notes

  • No interaction notes stored yet.